Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Sugammadex for Reversal of Neuromuscular Blockade
NCT00298831Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Oct 2005
- Primary completion
- May 2006
- Modality
- Biodegradable Polymers, Small Molecules
01
Overview
Phase 3, open-label, single-arm trial of Sugammadex in neuromuscular blockade (NMB), sponsored by Merck & Co. Primary endpoint: Time From Start of MK-8616 Administration to Recovery of the T4/T1 Ratio to 0.9 at 30 months. Started Oct 2005; status: completed.
02
Drugs
Sugammadex
03
Conditions
neuromuscular blockade (NMB)
Beyond the preview
Go deeper on NCT00298831.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00298831.